Genotype-phenotype correlations in X-linked myotubular myopathy

被引:107
作者
McEntagart, M
Parsons, G
Buj-Bello, A
Biancalana, V
Fenton, I
Little, M
Krawczak, M
Thomas, N
Herman, G
Clarke, A
Wallgren-Petterson, C
机构
[1] Univ Wales Coll Med, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales
[2] Ohio State Univ, Childrens Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Paediat, Columbus, OH 43210 USA
[4] Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP, Illkirch Graffenstaden, France
[5] Fac Med, Lab Diagnost Genet, Strasbourg, France
[6] CHRU, Strasbourg, France
[7] Hammersmith Hosp, Div Renal Med & Transplantat, London, England
[8] Univ Helsinki, Dept Med Genet, Helsinki, Finland
[9] Folkhalsan Dept Med Genet, Helsinki, Finland
关键词
X-linked; myotubular myopathy; genotype-phenotype correlation;
D O I
10.1016/S0960-8966(02)00153-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
X-linked myotubular myopathy is a severe congenital myopathy that presents in the neonatal period with profound hypotonia and an inability to establish spontaneous respiration. Usually death occurs in infancy from respiratory failure. However, there is phenotypic variability; a number of affected boys have achieved respiratory independence and become ambulatory. Disease-causing mutations have been identified throughout the MTM1 gene on Xq28. MTM1 encodes the protein myotubularin, which is expressed ubiquitously. The main objectives of this study were to establish whether the nature or site of the mutation in the MTM1 gene could predict severity of the disease and to investigate whether early intensive clinical intervention facilitated survival until spontaneous improvement occurred. An association was demonstrated between the presence of a non-truncating mutation of the MTM1 gene and the mild phenotype. However, many non-truncating mutations were also seen in association with the severe phenotype and these were not confined to recognized functional domains of the protein. This suggests that the use of mutation analysis to predict prognosis in the early period following diagnosis is limited. Unexpectedly, over 50 patients surviving for more than 1 year were identified in this study. Further information obtained on 40 of these cases revealed that 50% were receiving 24-h ventilatory support, while 27% were ventilated at night only. The high survival rate for this disorder therefore reflects intensive medical intervention without which the majority of these boys would not survive. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:939 / 946
页数:8
相关论文
共 22 条
[11]  
Laporte J, 2000, HUM MUTAT, V15, P393, DOI 10.1002/(SICI)1098-1004(200005)15:5<393::AID-HUMU1>3.0.CO
[12]  
2-R
[13]   Mutations in the MTM1 gene implicated in X-linked myotubular myopathy [J].
Laporte, J ;
GuiraudChaumeil, C ;
Vincent, MC ;
Mandel, JL ;
Tanner, SM ;
LiechtiGallati, S ;
WallgrenPettersson, C ;
Dahl, N ;
Kress, W ;
Bolhuis, PA ;
Fardeau, M ;
Samson, F ;
Bertini, E .
HUMAN MOLECULAR GENETICS, 1997, 6 (09) :1505-1511
[14]   A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast [J].
Laporte, J ;
Hu, LJ ;
Kretz, C ;
Mandel, JL ;
Kioschis, P ;
Coy, JF ;
Klauck, SM ;
Poustka, A ;
Dahl, N .
NATURE GENETICS, 1996, 13 (02) :175-182
[15]   Diagnosis of X-linked myotubular myopathy by detection of myotubularin [J].
Laporte, J ;
Kress, W ;
Mandel, JL .
ANNALS OF NEUROLOGY, 2001, 50 (01) :42-46
[16]   HIGH STATURE IN NEONATAL MYOTUBULAR MYOPATHY [J].
LEGUENNEC, JC ;
BERNIER, JP ;
LAMARCHE, J .
ACTA PAEDIATRICA SCANDINAVICA, 1988, 77 (04) :610-611
[17]   THE NATURAL-HISTORY OF CONGENITAL MYOTONIC-DYSTROPHY - MORTALITY AND LONG-TERM CLINICAL ASPECTS [J].
REARDON, W ;
NEWCOMBE, R ;
FENTON, I ;
SIBERT, J ;
HARPER, PS .
ARCHIVES OF DISEASE IN CHILDHOOD, 1993, 68 (02) :177-181
[18]   MYOTUBULAR MYOPATHY - PERSISTENCE OF FETAL MUSCLE IN AN ADOLESCENT BOY [J].
SPIRO, AJ ;
SHY, GM ;
GONATOS, NK .
ARCHIVES OF NEUROLOGY, 1966, 14 (01) :1-+
[19]   Characterization of 34 novel and six known MTM1 gene mutations in 47 unrelated X-linked myotubular myopathy patients [J].
Tanner, SM ;
Schneider, V ;
Thomas, NST ;
Clarke, A ;
Lazarou, L ;
Liechti-Gallati, S .
NEUROMUSCULAR DISORDERS, 1999, 9 (01) :41-49
[20]   Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate [J].
Taylor, GS ;
Maehama, T ;
Dixon, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :8910-8915